The U.S. Food and Drug Administration (FDA) approved Seglentis® (celecoxib and tramadol hydrochloride), a proprietary product developed by ESTEVE’s R&D team. This is ESTEVE's, CataloniaBio &  HealthTech member, first proprietary research product to enter the  United States market.

Seglentis® is the trade name for tablets that contain a co-crystal composed of celecoxib and tramadol hydrochloride. It is a new analgesic designed for acute pain  management in a multimodal treatment approach targeting four complementary pain  relief mechanisms. It offers a new treatment option for acute pain management aligned with the multimodal analgesia now considered standard of care.

The New ...

Grifols, a CataloniaBio & HealthTech member, welcomes the promising post-hoc analysis recently published by Biotest AG on the efficacy of trimodulin1 (IgM concentrate) in a relevant subgroup of severely ill COVID-19 patients.

In September, Grifols announced it entered into an agreement to acquire Tiancheng (Germany) Pharmaceutical  Holdings for EUR 1,100 million, the largest owner of Biotest AG. An alliance that will boost the availability of plasma-derived medicines and increase access for patients.

Less than one month after announcing the investment, Grifols welcomes Biotest’s recent and promising results: the analysis of the complete data set of ESsCOVID  (Escape from ...

MJN-neuro has opened crowdequity round of one million euros on the Capital  Cell platform to fund the business plan of the new device MJN-Seras, the first portable device that is able to predict the likelihood of suffering an epileptic seizure. The company, a CataloniaBio & HealthTech  member, has already exceeded one million euros in less than 5 months and expects to reach 120%. In addition, the round has been extended to allow the entry of a major Danish Family Office.

During this period, the value of the company has tripled, and, after the participation of American and Spanish investors, it ...

The investment company specializing in biotechnology and health, and a member of CataloniaBio & HealthTech, Capital  Cell, has raised 14 million euros. They are higher figures than the 13.5 million it raised throughout the 2020 financial year.

The director of the company, Daniel Oliver, sets the goal of reaching 16 million by the end of the current year. With this growth, Capital Cell could once again be the leader in crowdfunding in Spain in 2021.

Capital Cell was founded in 2015 as the first online investment platform in Europe specializing in biotechnology and health. Among the successes of the ...

A recent alliance between two CataloniaBio  & HealthTech members, the LEITAT  Technological Center and the Institute  for Bioengineering of Catalonia (IBEC), will give a new impulse in the development and application of cutting-edge technologies that will combine engineering and biology to find solutions to health problems. Both institutions have established a new agreement to promote innovation in different scientific and technological areas, including 3D bioprinting with bioinks.

The concept is based on an open creative space, in which researchers from both  institutions can collaborate with other institutions or companies from  different sectors, for the improvement and maturation of different technologies ...

The European Investment Bank (EIB) will provide Anaconda  Biomed, the medical device start-up and CataloniaBio & HelathTech  member, with venture debt funding of up to €10 million to support the  development of its second generation of catheter for the treatment of acute  ischemic stroke (AIS). This is the second venture debt operation in Spain backed by European Guarantee Fund (EGF) — part of the €540 billion EU response to the economic impact of COVID-19.

The EIB will provide long-term funding at favourable rates with flexible repayment. This will enable Anaconda Biomed to test the next generation of catheters to improve ...

Photo gallery

3D printing in the field of health is a well-established and well-known tool on a global scale. It called for the adaptation of the medical community, rethinking medical protocols, and has improved the efficiency and effectiveness of treatments. On the other hand, bioprinting still raises questions, but sounds like the new tool that could potentially revolutionize the industry.

CataloniaBio & HealthTech has debated the two tools in the 25th edition of the Lessons Learned forum, on October 7 at the Barcelona Science Park (PCB) and online (hybrid format) with entrepreneurs, hospitals and researchers from Catalonia working with them ...

BHV Partners, the venture builder specializing in the health sector and a member  of CataloniaBio & HealthTech, opens a new round of investment aimed at private investors in the health and financial sectors, to consolidate their growth. With this round of investment, it wants to raise 500,000 euros to  strengthen the professional team and develop its range of health projects.

Founded two years ago, BHV Partners has projects in its portfolio that are already advancing towards the market to offer solutions to unmet medical needs. These include Adan Medical, members of CataloniaBio &  HealthTech, who develop devices for anaphylaxis ...

Idneo  Medtech, member of  CataloniaBio & HealthTech, won the gold award in the 5th European Product Design Award in the Life Science Design, Medical, Scientific Machinery category for their design of the Universal Test Rider (UTR). The Universal  Test Reader (UTR) is Idneo Medtech's Point of Care solution that extends the functionality of conventional rapid test reader devices by developing the innovative vision of an AI-powered open test device able to interpret rapid tests from multiple vendors and formats. The UTR addresses analytical, epidemiological, and market needs, combining the quick, simple, inexpensive characteristics of rapid tests with the analytical robustness ...

Oxolife, a company associated with CataloniaBio  & HealthTech, has launched an international clinical trial to prove the effectiveness of its new treatment to improve the female fertility rate. It is the largest phase II study on female fertility conducted in Spain and it is aimed to improve the implantation of the embryo and increase the success rate of pregnancy, an unmet medical need as there is no therapy to improve embryonic implantation.

The trial has begun thanks to the round of  investment of 5 million euros that Oxolife captured in June 2020, which led Inveready together with the Center for ...

Mediktor, the healthtech company which provides a sophisticated pre-diagnosis medical assistant and a CataloniaBio & HealthTech  member, announced that it has raised a €11 million financing round to  keep on improving their elaborate technology and expand their international  presence.

The round was led by European healthtech growth capital investor MTIP. Existing investor Alta Life Sciences, also a CataloniaBio &  HealthTech member, participated as well.

Its technology identifies patient’s symptoms using natural language recognition, allowing the interpretation of more than one symptom at the same time. In the conversation with the medical assistant the questions require only simple responses and are ...

Inbiomotion, a CataloniaBio &HealthTech member, is developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients.  They recently announced the publication of the resultsof the prospectively-planned, retrospective analysis of clinical outcome data from a new clinical study in Journal of the National Cancer Institute, Cancer Spectrum.  The data show that in patients with MAF-negative tumors (determined with Inbiomotion’s proprietary MAF Test®), adjuvant treatment with clodronate was associated with a significant benefit in overall survival compared to placebo-treated control patients receiving the same standard of care.

Results confirm the company’s previous data (AZURE trial analyses ...

After postponing it due to COVID-19, the tenth edition of BIOSPAIN was held the last week of September, from 27 to 30, online all the days and in-person on 29 and 30 in Pamplona.  It has been one of the first major events in the sector during the pandemic with the participation of a thousand professionals, half of them in-person, from about 600 entities in 30 different countries.  More than 2,000 one-on-one meetings between national and international professionals and investors have been closed online and in person.

Sessions and round tables were the forum for discussion, to address issues ...

Nuage Therapeutics has announced the closing of a financing round by Sabadell Asabys, the investment vehicle managed by Asabys Partners, members of CataloniaBio & HealthTech. With this injection of capital, the spin-off will start its work discovering drugs aimed at therapeutic targets currently considered undruggable.

Based at the Barcelona Science Park, Nuage Therapeutics uses a proprietary assay to discover new drugs for the treatment of castration-resistant prostate cancer. Further pre-clinical programs will be announced in the coming months. The scientists behind Nuage Therapeutics have spent years investigating target proteins currently considered undruggable  due to their unique structural properties.

The financing ...

The health sector is a rising sector. Investment in health start-ups in Catalonia doubles in just two years, to over €200 million in 2020, and Barcelona has climbed to fifth place in Europe in rounds of investment in digital health. This is shown by the data collected in the BioRegion  of Catalonia Life Sciences and Healthcare Outlook 2020, by CataloniaBio & HealthTech and Biocat, which has motivated a series of special articles to give visibility to some of the projects that are representative of the strengths of the Catalan sector.

One of the keys to success is the previous innovative ...

GoodGut, a CataloniaBio  & HealthTech member, dedicated to early diagnoses to improve digestive health, will now also form part of HIPRA’s  strategy to continue delivering innovative solutions to patients. One of the most innovative products in its portfolio is the RAID-CRC  test, which enables the quick, early and precise detection of colorectal cancer.

The GoodGut company, located at the Science and Technological Park of the University of Girona, was founded by Mariona Serra Pagès, Xavier Aldeguer, Jesús Garcia-Gil and Jaume Amat in 2014 as a spin-off of the University of Girona and the Dr. Josep Trueta Biomedical Research Institute ...

CataloniaBio & HealthTech, aiming to promote the interests of the business network of the sector, has joined Barcelona Global in the initiative to review and  provide feedback on the Spanish draft law that will affect and regulate start-ups. The document was submitted within the public participation period, which closed at the end of July.

The draft law presented by the Spanish government is welcomed as a first step towards the creation of a legal and fiscal framework to promote entrepreneurship in Spain. The document lists some measures that the sector has long been calling for, but much remains to meet ...

Banco Sabadell is launching the fourth edition of BStartup Health call for proposals to support three early stage start-ups in the healthcare sector with an investment of €100,000 and strategic mentoring. The deadline for applications is 30 September 2021.

The projects will be evaluated based on their potential for growth and scalable, innovative business models.

The scientific committee is made up of Clara Campàs, founding partner at Asabys; Carlos Gallardo, CEO of CG Health and Almirall board member; Damià Tormo, partner of Columbus Venture Partners and CEO of Artax Biofarma; and Montserrat Vendrell, partner at Alta Life Science and ...

Devicare, member of CataloniaBio &  HealthTech and one of the leading biotechnology companies in urology in the state, continues its growth plan by entering the Pharmacy for the first time. Through an agreement with Difefac Pharma, which will distribute its Nodorin® 30 ml  and Urogelus® 125 ml products, intended for urological hygiene.

The biotech company, which recently closed a round of financing with Advanced MedTech Holdings, has reached an agreement with Difefac Pharma, a leading company in the exclusive distribution and marketing of Pharmacy and Parapharmacy products, with the aim of ensuring the presence of these products in all pharmacies ...

Onalabs, CataloniaBio & HealthTech  member, launches a round of investment of 1.2 million euros to develop two digital devices for home hospitalization of chronic patients and sports medicine based on sensory bioengineering. The devices act as microlaboratories turning the skin into a data platform. The company, which has already raised an equal amount on competitive funds, has launched three different private investment  channels: Onalabs Investment, direct investors and the international  crowdfunding platform Crowdcube.

The injection of this capital should allow to accelerate the market launch of two of the three devices under development by Onalabs in the first half ...